Fortress Biotech (FBIO) and Partex said Monday that they are collaborating to identify and evaluate biopharmaceutical compounds using artificial intelligence for potential acquisition or licensing by Fortress.

The project will use Partex's AI-based drug discovery and development platform, the companies said.

Financial details weren't provided.

Fortress shares were rising 1.8% in early trading Monday.